---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-009320"
form_type: "8-K"
ticker: "GLUE"
cik: "0001826457"
company_name: "Monte Rosa Therapeutics, Inc."
filed_at: "2023-03-23T23:59:59+00:00"
generated_at: "2026-06-17T19:10:07.800834+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Monte Rosa Therapeutics appoints Jan Skvarka to Board of Directors

## Summary
- Appointed Jan Skvarka, Ph.D., MBA to the Board, effective March 23, 2023.
- Skvarka will serve as a Class I director until the 2025 annual meeting.
- Board determined Skvarka is independent under Nasdaq listing standards.
- Compensation follows Non-Employee Director Compensation Policy; entered indemnification agreement.
- No arrangements or transactions requiring disclosure under Item 404(a) of Regulation S-K.

## SEC filing metadata
- accession: 0000950170-23-009320
- form_type: 8-K
- ticker: GLUE
- cik: 0001826457
- company_name: Monte Rosa Therapeutics, Inc.
- filed_at: 2023-03-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826457/000095017023009320/0000950170-23-009320-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826457/000095017023009320/glue-20230323.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-009320
- JSON: https://secwatch.observer/filing/0000950170-23-009320.json
- Plain text: https://secwatch.observer/filing/0000950170-23-009320.txt

## Key facts
- Executive change
  Jan Skvarka was appointed as Director at Monte Rosa Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: the Board appointed Jan Skvarka, Ph.D., MBA to join the Board, effective as of March 23, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1826457/000095017023009320/0000950170-23-009320-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.